News Research Lung Cancer Pathology Prognostic & Predictive Models

Multimodal Model Uses Pathology Data to Predict Immunotherapy Response in NSCLC

Combining pathomics, radiomics, and clinicopathologic data, an AI model outperformed current tools for predicting response to single-agent or combination immunotherapy in non–small cell lung cancer (NSCLC).

April 21, 2026 By Lisa Astor 6 min read
Share
-0:00/0:00

ASCO AI in Oncology is published by Conexiant under a license arrangement with the American Society of Clinical Oncology, Inc. (ASCO®). The ideas and opinions expressed in ASCO AI in Oncology do not necessarily reflect those of Conexiant or ASCO. For more information, see Policies.

KOL Commentary
Watch

Related Content